Dr. Grover is an immunologist, entrepreneur and innovator. He has worked with National Institutes of Health, Scripps Research and sits on the board of the American Nutrition Association. Dr. Grover was an Adjunct Professor in the Synthetic Biology and Bio-energy Group at J Craig Venter Institute, La Jolla, California where he shares his expertise in immunology, cell and molecular biology. His entrepreneurial activities revolve around AJELES Inc and AJLIS Holdings Inc, two companies he cofounded in 2019. Both companies focus on diverse approaches to healthy longevity. Dr. Grover also actively works as a strategic advisor to companies dedicated to regenerative medicine; nutraceutical-based health solutions, and venture capital funds with emphasis on healthcare. Dr. Grover has been highly active in startup companies.
As a former leader and an executive board member of the University of California, San Diego (UCSD) Entrepreneur Challenge (a business plan competition), he has advised and consulted dozens of startups across consumer brands, drugs, diagnostics, health, food, mobile/software, and hardware on their business plans. He has also been a Mentor board member for Indiebio, the world’s biggest biotechnology accelerator based in San Francisco. Dr. Grover also served as Co-founder of Nurish.me, a wellness based nutraceutical company focused on inflammation where he helped to accelerate go-to market strategies, strategic partnerships, marketing, distribution, corporate fund raising, and compliance.
His research work has been published in top scientific journals such as Science, Proceedings of National Academy of Sciences, Journal of American Medical Association (JAMA), Nature Reviews, and American Journal of Transplantation. He holds multiple patents. His work has been featured on PBS, DER SPIEGEL Magazine, Journal of American Medical Association (JAMA), Nature Reviews, American Journal of Transplantation, San Diego Union Tribune and various news outlets around the world. He is a featured expert on TV show and community public speaking platforms.